LONDON, UK, and Lexington, MA, USA - 27 September 2007 -- SkyePharma PLC (LSE:
SKP) and its US marketing partner, Critical Therapeutics, Inc (Nasdaq: CRTX)
announce the nationwide US launch today of ZYFLO CR(TM)(zileuton)
extended-release tablets for the prevention and chronic treatment of asthma in
adults and children 12 years of age and older.
